Binding of chloroquine–conjugated gold nanoparticles with bovine serum albumin

We have conjugated chloroquine, an anti-malarial, antiviral and anti-tumor drug, with thiol-functionalized gold nanoparticles and studied their binding interaction with bovine serum albumin (BSA) protein. Gold nanoparticles have been synthesized using sodium borohydride as reducing agent and 11-mercaptoundecanoic acid as thiol functionalizing ligand in aqueous medium. The formation of gold nanoparticles was confirmed from the characteristic surface plasmon absorption band at 522 nm and transmission electron microscopy revealed the average particle size to be ∼7 nm. Chloroquine was conjugated to thiolated gold nanoparticles by using EDC/NHS chemistry and the binding was analyzed using optical density measurement and Fourier transform infrared spectroscopy. The chloroquine–conjugated gold nanoparticles (GNP–Chl) were found to interact efficiently with BSA. Thermodynamic parameters suggest that the binding is driven by both enthalpy and entropy, accompanied with only a minor alteration in protein’s structure. Competitive drug binding assay revealed that the GNP–Chl bind at warfarin binding site I in subdomain IIA of BSA and was further supported by Trp212 fluorescence quenching measurements. Unraveling the nature of interactions of GNP–Chl with BSA would pave the way for the design of nanotherapeutic agents with improved functionality, enriching the field of nanomedicine.

We report the synthesis of chloroquine–conjugated gold nanoparticles and their binding to bovine serum albumin using biophysical and docking studies.Figure optionsDownload high-quality image (127 K)Download as PowerPoint slideResearch highlights
► Synthesis and characterization of drug (chloroquine)–conjugated gold nanoparticles (GNP–Chl).
► Binding of GNP–Chl with bovine serum albumin (BSA) using biophysical techniques.
► Docking of drug with BSA.